Venclexta (Venetoclax) — NZ Medication Guide | KiwiMeds
✅ Reviewed by Ramon Wong, BPharm, Registered Pharmacist (New Zealand) | May 2026 — This information is for educational purposes only and is not a substitute for personalised advice from your doctor or pharmacist. Always seek professional guidance before making changes to your medications.
What is Venclexta (venetoclax)?
Venclexta (generic name: venetoclax) is a targeted cancer medicine used to treat chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) — types of blood cancer. It belongs to a class of medicines called BCL-2 inhibitors. Venetoclax is an oral tablet taken at home, which means many people do not need regular hospital infusions for their treatment.
What is it used for? (NZ context)
In New Zealand, venetoclax (Venclexta) is funded by Pharmac for adults with chronic lymphocytic leukaemia (CLL). From 1 May 2026, Pharmac funds:
● Venetoclax + ibrutinib — as a first-line (frontline) combination treatment for CLL
● Venetoclax + obinutuzumab — as a first-line combination treatment for CLL
People who have been self-funding venetoclax or ibrutinib may also be eligible to switch to the funded combination treatments. CLL is a slow-growing blood cancer that cannot be cured, but most people can live well for many years with the right treatment. Around 110 people are expected to benefit from the funded combinations each year. See the Pharmac announcement for eligibility details. Always check with your haematologist or oncologist about your specific eligibility.
How does it work?
Venetoclax works by blocking a protein called BCL-2 (B-cell lymphoma 2). Cancer cells — including CLL cells — rely on BCL-2 to survive and resist normal cell death. By blocking BCL-2, venetoclax essentially switches off this survival signal, causing the cancer cells to self-destruct (a process called apoptosis). Venetoclax targets CLL cells specifically, making it more targeted than traditional chemotherapy. When combined with ibrutinib or obinutuzumab, the medicines attack CLL cells in different ways at the same time, which can improve response rates and help people achieve longer periods of remission.
How to take it
Venetoclax (Venclexta) is taken as a tablet by mouth, usually once daily with food.
Because venetoclax can cause a serious side effect called tumour lysis syndrome (TLS) when first started, it is always introduced gradually over several weeks using a dose ramp-up schedule — starting low and increasing slowly. Your specialist will supervise this process closely, usually with blood tests and sometimes hospital monitoring during the initial doses.
Typical dose ramp-up for CLL: 20 mg → 50 mg → 100 mg → 200 mg → 400 mg over 5 weeks. Your haematologist will give you a specific schedule. Do not stop, start, or change your dose without talking to your specialist first.
Take your tablet at the same time each day. Swallow whole — do not crush or chew. Grapefruit and grapefruit juice should be avoided as they can increase venetoclax blood levels.
Common side effects
Most people taking venetoclax experience some side effects, especially at the start. Common ones include:
- Nausea and diarrhoea
- Fatigue (tiredness)
- Low white blood cell counts (neutropenia) — makes you more prone to infections
- Low red blood cell counts (anaemia)
- Low platelet counts
- Upper respiratory infections (colds, chest infections)
- Constipation
- Muscle aches and joint pain
Serious side effects to watch for
Tumour lysis syndrome (TLS) is the most important serious side effect. When venetoclax kills many cancer cells quickly at the start of treatment, the breakdown products can build up in the blood and cause kidney damage, abnormal heart rhythms, or seizures. This is why treatment is started at a very low dose and increased slowly, and why close monitoring is essential.
Contact your doctor or go to hospital urgently if you experience:
- Nausea, vomiting, diarrhoea, or feeling very unwell shortly after starting or increasing your dose
- Muscle cramps or spasms
- Irregular heartbeat or chest pain
- Passing less urine than usual
- Signs of serious infection: fever, chills, difficulty breathing
- Unusual bruising or bleeding
Important drug interactions
Venetoclax is broken down by an enzyme called CYP3A4, so many medicines can significantly increase or decrease its blood levels:
Avoid (significantly increases venetoclax levels, increases TLS risk):
- Strong CYP3A4 inhibitors: ketoconazole, itraconazole, clarithromycin, ritonavir, posaconazole, voriconazole
- Grapefruit, grapefruit juice, Seville (bitter) oranges
Avoid (reduces venetoclax effectiveness):
- Strong CYP3A4 inducers: rifampicin, carbamazepine, phenytoin, St John’s Wort
Also discuss with your specialist:
- Blood thinners (warfarin, aspirin, NSAIDs)
- Any new prescription, over-the-counter, or herbal medicines
Things to avoid while taking it
- Grapefruit and grapefruit juice — increases venetoclax levels in your blood
- Seville/bitter oranges — same interaction as grapefruit
- Live vaccines — venetoclax lowers your immune system; discuss any upcoming vaccines with your specialist
- Contact with sick people — your immune system is weakened; avoid crowds when your white cell count is low
- Starting new medicines without checking — many medicines interact with venetoclax
NZ-specific information
Brand name in NZ: Venclexta
Funded: Yes — from 1 May 2026 for CLL (in combination with ibrutinib or obinutuzumab as first-line treatment, and ibrutinib alone as second-line)
Available as: Oral tablets (10 mg, 50 mg, 100 mg)
Special Authority: Required — your haematologist or oncologist will apply on your behalf
Prescription type: Hospital specialist prescription required
Previously, venetoclax was not funded in NZ for first-line CLL treatment and patients had to pay privately (up to thousands of dollars per month). This is a significant change for New Zealanders living with CLL.
Frequently asked questions
Can I take venetoclax at home?
Yes — venetoclax is a tablet taken at home. However, when you first start, your specialist may ask you to attend clinic or even stay in hospital for the first few doses to monitor for tumour lysis syndrome.
How long will I need to take it?
When used in combination with ibrutinib for CLL, treatment duration is typically fixed (e.g., 12 cycles of venetoclax + a set period of ibrutinib). Your specialist will tell you your specific plan.
Will venetoclax cure my CLL?
CLL currently cannot be cured, but venetoclax combinations can help many people achieve deep remissions — meaning very little or no detectable cancer — for extended periods.
What if I miss a dose?
If less than 8 hours have passed, take the missed dose. If more than 8 hours have passed, skip it and take the next dose as normal. Do not double up.
Related medications
- Ibrutinib (Imbruvica) — often combined with venetoclax for CLL
- Obinutuzumab (Gazyvaro) — combined with venetoclax for CLL